Ontozry (Cenobamate)

Cenobamate, the active ingredient in Ontozry, is a sodium channel blocker presented as an oral dosage form for oral use. It is indicated for the treatment of partial‑onset seizures in patients with epilepsy. GNH USA supplies Ontozry as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Cenobamate is used as an antiepileptic agent targeting seizure activity.

- Partial‑onset seizures: reduces seizure frequency and severity in patients with focal epilepsy. - Epilepsy: provides adjunctive therapy for adults with uncontrolled focal seizures despite other treatments. - Adjunctive seizure control: enhances overall seizure management when combined with other antiepileptic drugs.

Cenobamate may cause a range of adverse reactions.

Common Side Effects: - Dizziness: sensation of light‑headedness or unsteadiness. - Somnolence: excessive sleepiness or fatigue. - Nausea: feeling of stomach upset or urge to vomit. - Headache: mild to moderate head pain. - Diplopia: double vision. - Balance disorder: difficulty maintaining equilibrium.

Serious or Rare Side Effects: - Hyponatremia: low blood sodium levels requiring monitoring. - Rash or Stevens‑Johnson syndrome: severe skin reactions. - Suicidal ideation: thoughts of self‑harm. - Severe respiratory depression: difficulty breathing. - Hepatotoxicity: liver enzyme elevations. - Cardiac arrhythmias: irregular heart rhythms.

Cenobamate requires careful monitoring and patient counseling.

- Baseline labs: obtain electrolytes and liver function tests before initiation. - Dose titration: increase gradually to minimize adverse effects. - Concomitant CNS depressants: monitor for enhanced sedation. - Pregnancy: avoid use unless benefits outweigh potential risks. - Renal/hepatic impairment: adjust dosing as clinically indicated. - Store at room temperature: keep in original container, protect from moisture and direct sunlight.

Cenobamate interacts with several medications that may alter its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase cenobamate levels. - Carbamazepine, phenytoin, phenobarbital: may reduce cenobamate concentration. - Other sodium channel blockers (e.g., lamotrigine): risk of additive toxicity.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inducers (e.g., rifampin): may lower cenobamate exposure. - Antidepressants (e.g., fluoxetine): potential for increased CNS depression. - Anticoagulants (e.g., warfarin): monitor INR for possible changes.